The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc.

New York, New York – (Newsfile Corp. – June 3, 2021) – Vincent Wong’s law firms announce that a class action lawsuit has been initiated on behalf of investors who have purchased Emergent Biosolutions Inc. (“Emergent Bio”) . (NYSE: EBS) between July 6, 2020 and March 31, 2021.

If you have suffered a loss, contact us at the link below. There are no costs or obligations for you.

Allegations against EBS include that the company made materially false and / or misleading information and / or failed to disclose: (i) Emergent’s Baltimore facility has had a history of production problems that increase the likelihood of massive contamination; (ii) these long-standing contamination risks and quality control issues at Emergent’s facility resulted in a number of FDA citations; (iii) the company previously had to dispose of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants’ public statements regarding Emergent’s ability and capacity to mass-produce multiple COVID-19 vaccines at its Baltimore manufacturing facility were materially false and / or misleading and / or unfounded .

If you have suffered a loss in Emergent Bio, you have until June 18, 2021 to petition for the court to appoint you as the lead plaintiff. Your ability to partake in a recovery does not require you to be the lead plaintiff.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities disputes related to financial fraud and shareholder violations. Lawyer advertising. Previous results do not guarantee similar results.

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Telephone number. 212.425.1140
Fax. 866.699.3880
Email: [email protected]

To view the source version of this press release, please visit

Comments are closed.